The global Peptide Therapeutics Market is estimated to be valued at US$ 44,386.9 Mn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Peptide therapeutics refers to peptide-based drugs that provide therapeutic effects in metabolic diseases such as diabetes. The small size and low molecular weight of peptides help in easy absorption and increased bioavailability. Cell penetrating peptides are broadly used in peptide-based drug delivery due to their ability to penetrate cellular membranes without exploiting endocytosis pathways.
Market Overview:
Peptide therapeutics are protein fragments that mimic an existing natural hormone or other substance and provide disease-modifying therapeutic effects. They provide targeted action, reduce side effects, and improve patient compliance compared to conventional large molecule drugs.
Market key trends:
One of the major trends in the peptide therapeutics market is the growing demand for cell penetrating peptides. Cell penetrating peptides possess the ability to penetrate cell membranes without utilizing receptor-mediated endocytosis pathways. They reversibly interact with membrane phospholipids and facilitate permeation of co-administered bioactive cargos across the plasma membrane. Companies are extensively researching on the development of efficient cell penetrating peptides for delivery of therapeutic agents like proteins and nucleic acids. For instance, Pep1, tat, and penetratin cell penetrating peptides are being investigated for tumor-targeted drug delivery applications.
Segment Analysis
The global peptide therapeutics market can be segmented based on product type, route of administration, synthesis technology, therapeutic application, and end user. Based on product type, the market is categorized into generic and branded. The branded segment currently dominates the market due to the high cost associated with the development of novel peptide therapeutics and limited competition from generic drugs during the patent period.
Based on route of administration, the market is classified into parenteral, oral, and others. The parenteral segment holds the largest share due to better absorption and bioavailability of peptides through injection.
Key Takeaways
The Global Peptide Therapeutics Market Size is expected to witness high growth, exhibiting a CAGR of 6.6% over the forecast period, due to increasing prevalence of metabolic disorders, cancer, gastrointestinal disorders, and infectious diseases.
Regional analysis - North America currently dominates the global peptide therapeutics market owing to high healthcare expenditure and presence of major players in the region. Asia Pacific is expected to exhibit the fastest growth over the forecast period due to increasing healthcare expenditure, rising geriatric population, and growing penetration of peptide therapeutics in the region.
Key players - Key players operating in the peptide therapeutics market are Teva Pharmaceutical Industries Ltd, Novo Nordisk A/S, OPKO Health Inc., Lilly, Hanmi Pharm.Co., Sanofi, Circle Pharma, Pfizer Inc., Novartis AG, PeptiDream Inc., Amgen Inc., AstraZeneca, Bachem Holding AG, CordenPharma International, Ipsen Pharma, Merck KGaA, PolyPeptide Group, Bayer AG. These companies are focusing on new product launches and strategic collaborations with biotech firms and research institutes to strengthen their presence in the peptide therapeutics market.
Read more: https://www.ukwebwire.com/peptide-therapeutics-market-insights-trends/
Comments
0 comment